Gary R. Lichtenstein, MD
Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Member GI Division Executive Committee, University of Pennsylvania
2023, 2024, 2025
Vice Chief, Division of Gastroenterology and Hepatology, Development and Philanthropy, University of Pennsylvania Health System
2023, 2024, 2025, ongoing
Department: Medicine
Contact information
3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
Fax: 215-349-5915
Publications
Education:
BA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Permanent linkBA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Description of Research Expertise
My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease
Description of Clinical Expertise
Inflammatory Bowel DiseaseCrohn's Disease
Ulcerative Colitis
Selected Publications
Lichtenstein GR : Exploring the Use of Terlipressin in Candidates for Liver Transplant. Gastroenterol Hepatol (N Y) 21(8): 467, August 2025.Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F, Kane S: ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. American Journal of Gastroenterology 120(7): 1447-1473, July 2025.
Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR. : Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology July 2025.
Lichtenstein GR: Exploring Irritable Bowel Syndrome Symptoms in Patients with Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 21(7): 407, July 2025.
Lichtenstein GR: Examining Exercise in Metabolic Dysfunction-Associated Steatohepatitis. Gastroenterol Hepatol (N Y) 21(6): 339, June 2025.
Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY.: ACG Clinical Guideline: Management of Crohn's Disease in Adults. American Journal of Gastroenterology 120(6): 1225-1264, June 2025.
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S.: Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study. Lancet Gastroenterology Hepatology June 2025.
Panaccione R, Lichtenstein GR, Colombel JF, Nakase H, Cheng E, Klaff J, et al.: Efficacy and Safety of Upadacitinib After 4 Years of Treatment in Patients with Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Lable Extension Study (U-Activate). . Gastroenterology May 2025.
Khanna T, Sehgal P, Wang Y, Lichtentein GR.: Real World Comparative Effectiveness of Upadacitinib Versus Tofacitinib in Ulcerative Colitis: A Propensity Matched Analysis. Gastroenterology May 2025.
Lichtenstein GR, Allegretti JR, Riubin DT, Feagan BG, Bressler B, Panés J, et al. : Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. Gastroentrology May 2025.